In this video, Tara Mitchell, MD, examines a recent phenomenon, the successful long-term treatment of patients with melanoma metastatic to the brain. Reviewing three recent reports presented at ASCO 2017 (Checkmate 204, ABC and Combi MG), Dr. Gangadhar describes the targeted immunotherapies in these trials, their application as up-front therapy in select patients (asymptomatic, steroid-naive) and their result: durable partial or complete responses in the majority of treated patients in the absence of neurosurgery or radiation therapy. Also discussed: combination local/systemic therapy and the need for increased radiological monitoring in treated patients.
Related Links:
Published
November 17, 2017
Created by
BROADCASTMED